The 2026 paper reports no trial results because it is a protocol, not a completed study. It lays out how researchers plan to test oral probiotics plus topical MSC secretome for acne vulgaris.
MSC secretome means the mix of proteins and small vesicles collected from mesenchymal stem cells grown in the laboratory. The paper explains the rationale and study methods. It does not report patient outcomes.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the 2026 paper actually publish?
- What will the 64-patient trial test?
- Why do earlier probiotic studies not settle product choices?
- Should you pay for secretome or exosome acne treatment now?
What did the 2026 paper actually publish?
Lestari and colleagues published a Phase 2 double-blind randomised trial protocol for acne vulgaris. BMJ Open published the plan on June 4, 2026, with rationale and methods but no clinical results, described in the trial protocol. A protocol tells other scientists what will be done and why. Readers can judge the design before results appear.
They cannot judge whether the treatment worked. This distinction matters for acne-prone skin. A promising idea is not proof of clearer skin. Results come only after patients finish treatment and researchers analyze the data.
What will the 64-patient trial test?
The planned trial enrolls 64 people with mild-to-moderate acne vulgaris. Treatment lasts eight weeks across four parallel groups, according to Veeva in the trial listing. Each group receives standard acne therapy plus a different combination. The combinations pair active or placebo oral probiotics with active or placebo topical secretome.
This four-arm design separates the effect of each added treatment. The prespecified goals are lower acne severity and better microbiome balance. Measurements compare baseline against post-therapy skin and microbial findings. The registry frames these as questions to test, not benefits already proven.
Why do earlier probiotic studies not settle product choices?
A December 2025 systematic review examined double-blind acne probiotic trials. Formulations differed widely in strains, colony-forming units, viability, excipients, vehicles and duration. That variation limits direct use for shoppers. A product on a shelf may use a different strain, dose or base.
It may also be used for a different length of time. Treatment length matters because gut and skin responses take time. Vehicle matters because creams, gels and capsules deliver ingredients differently. Without matching details, one trial result does not transfer to another product.
Should you pay for secretome or exosome acne treatment now?
Wiley Dermatological Reviews reports that MSC-derived secretome and exosome therapies for skin disease remain largely experimental, with early signals but no FDA- or EMA-approved dermatologic product, detailed in the dermatology review. U.S. dermatology reporting also states that no exosome product has FDA approval for any skin indication.
Cell-derived products that claim to treat disease face drug or biologic review. Cosmetic labels do not clear that hurdle. For acne-prone skin, the practical path is narrow:.
- Continue proven standard therapy prescribed for your acne severity.
- Do not replace it with an unapproved secretome or exosome offer.
- Wait for the controlled 64-patient, eight-week results before judging this combination.
- If a clinic urges purchase, ask for the FDA clearance letter in writing.
You Might Also Like
- The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: Evidence Limits and Open Questions for People With Acne-Prone Skin
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: Evidence Limits and Open Questions for People With Acne-Prone Skin
- Protective and Acne-Associated Microbial Strains in the 2026 Consensus: Evidence Limits and Open Questions for People With Acne-Prone Skin